SCHEMBL2412706

SCHEMBL2412706

CN(C)c1ccc(-c2ccc(OCCc3csc(SC(C)(C)C(=O)O)n3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 2/20 0.41
PPARA Q07869 8/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
RAB9A P51151 2/20 0.37
PPARG P37231 7/20 0.37
HDAC1 Q13547 1/20 0.35
MAPT P10636 3/20 0.35
TP53 P04637 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
MCL1 Q07820 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PPARD Q03181 1/20 0.34
LTA4H P09960 2/20 0.33
LTB4R Q15722 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2415153 0.90 PPARA (0.45) SLC22A12PPARASMN1; SMN2RAB9APPARG
SCHEMBL2398837 0.89 RAB9A (0.49) SLC22A12PPARASMN1; SMN2RAB9APPARG
SCHEMBL2419262 0.89 PPARA (0.46) SLC22A12PPARASMN1; SMN2RAB9APPARG
SCHEMBL2410536 0.88 PPARA (0.43) SLC22A12PPARASMN1; SMN2PPARGMAPT
SCHEMBL2413109 0.86 SLC22A12 (0.46) SLC22A12PPARAHDAC1MAPTALDH1A1
SCHEMBL2413963 0.86 PPARA (0.45) SLC22A12PPARAPPARGTP53PPARD
SCHEMBL2410233 0.86 SHMT2 (0.42) PPARASMN1; SMN2RAB9APPARGHDAC1
SCHEMBL12271616 0.85 SLC22A12 (0.41) SLC22A12PPARASMN1; SMN2RAB9APPARG
SCHEMBL2411523 0.85 PDE10A (0.47) PPARAPPARGMAPTALDH1A1
SCHEMBL2408631 0.84 PPARD (0.46) SLC22A12PPARASMN1; SMN2RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US claimed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG SLC22A12 920/4885PPARA 1/4885SMN1; SMN2 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.